Document is current
Any future updates will be listed below
-
Authors
Adnan Awad, Shady https://orcid.org/0000-0001-6205-7799
Brück, Oscar https://orcid.org/0000-0002-7842-9419
Shanmuganathan, Naranie https://orcid.org/0000-0001-5895-8797
Jarvinen, Timo
Lähteenmäki, Hanna
Klievink, Jay
Ibrahim, Hazem https://orcid.org/0000-0003-0165-2660
Kytölä, Soili
Koskenvesa, Perttu
Hughes, Timothy P. https://orcid.org/0000-0002-0910-3730
Branford, Susan https://orcid.org/0000-0002-5095-7981
Kankainen, Matti https://orcid.org/0000-0002-4714-9481
Mustjoki, Satu https://orcid.org/0000-0002-0816-8241
- License Information
-
More Information
Article History
Received: 21 December 2021
Revised: 29 March 2022
Accepted: 30 March 2022
First Online: 20 April 2022
Competing interests
: S.A.A. has received research funding from Incyte. O.B. has received honoraria from Novartis and Sanofi. S.B. is a member of the advisory boards of Qiagen, Novartis, and Cepheid and has received honoraria from Qiagen, Novartis, Bristol–Myers Squibb, Incyte, and Cepheid, as well as research support from Novartis and Cepheid. T.P.H. and S.M. have received honoraria and research funding from Novartis, Pfizer, and Bristol–Myers Squibb (not related to this study).
